News | January 21, 2026
iRegene’s Parkinson’s therapy gains FDA designation
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants
If approved, tavapadon will enhance AbbVie's leadership in Parkinson's disease by providing patients with a once daily oral treatment option
PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Parkinson's disease (PD) is one of the most common neurological disorders caused by the death of dopamine-secreting neurons in the brain
Subscribe To Our Newsletter & Stay Updated
